Abstract
Many protein tyrosine kinases (PTK), including Janus kinase 3 (JAK3) and Bruton ’ s tyrosine kinase (BTK), have been recently identified as potential drug targets to treat diverse diseases including inflammation and cancer. The wealth of structural information currently available for protein kinase-inhibitor complexes facilitates the structure-based design of novel kinase inhibitors. In this report, we discuss the structural basis of protein kinase inhibitor design and the common binding features of small molecule kinase inhibitors including pyridinyl imidazoles, purines, oxindoles, anilinoquinazolines and isoquinalines. The structural features of targeted kinase proteins and their inhibitor complexes are discussed with respect to their structure-and-activity relationships (SAR). We present a structural comparison of kinase inhibitors with a special emphasis on inhibitors of JAK3 and BTK.
Keywords: structure-based drug design, ptk, sar, btk, jak3, computational chemistry, inflammation, leukemia
Current Pharmaceutical Design
Title: Tyrosine Kinases as New Molecular Targets in Treatment of Inflammatory Disorders and Leukemia
Volume: 10 Issue: 10
Author(s): Fatih M. Uckun and Chen Mao
Affiliation:
Keywords: structure-based drug design, ptk, sar, btk, jak3, computational chemistry, inflammation, leukemia
Abstract: Many protein tyrosine kinases (PTK), including Janus kinase 3 (JAK3) and Bruton ’ s tyrosine kinase (BTK), have been recently identified as potential drug targets to treat diverse diseases including inflammation and cancer. The wealth of structural information currently available for protein kinase-inhibitor complexes facilitates the structure-based design of novel kinase inhibitors. In this report, we discuss the structural basis of protein kinase inhibitor design and the common binding features of small molecule kinase inhibitors including pyridinyl imidazoles, purines, oxindoles, anilinoquinazolines and isoquinalines. The structural features of targeted kinase proteins and their inhibitor complexes are discussed with respect to their structure-and-activity relationships (SAR). We present a structural comparison of kinase inhibitors with a special emphasis on inhibitors of JAK3 and BTK.
Export Options
About this article
Cite this article as:
Uckun M. Fatih and Mao Chen, Tyrosine Kinases as New Molecular Targets in Treatment of Inflammatory Disorders and Leukemia, Current Pharmaceutical Design 2004; 10 (10) . https://dx.doi.org/10.2174/1381612043452677
DOI https://dx.doi.org/10.2174/1381612043452677 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recognition of Lung Adenocarcinoma-specific Gene Pairs Based on Genetic Algorithm and Establishment of a Deep Learning Prediction Model
Combinatorial Chemistry & High Throughput Screening Myricanol-9-acetate, a Novel Naturally Occurring Derivative of Myricanol, Induces ROS-dependent Mitochondrial-mediated Apoptosis in MCF-7 Cancer Cells
Current Topics in Medicinal Chemistry Formulation Development and Evaluation of Transdermal 5-Fluorouracil Ethosomal Formulation through 2<sup>5-2</sup> Fractional Factorial Design
Drug Delivery Letters Imaging of HER-2 Overexpression in Tumors for Guiding Therapy
Current Pharmaceutical Design The Accomplices of NF-κB Lead to Radioresistance
Current Protein & Peptide Science Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication
Anti-Cancer Agents in Medicinal Chemistry When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity
Anti-Cancer Agents in Medicinal Chemistry Opioid Growth Factor and its Derivatives as Potential Non-toxic Multifunctional Anticancer and Analgesic Compounds
Current Medicinal Chemistry Varlitinib Mediates Its Activity Through Down Regulating MAPK/EGFR Pathway in Oral Cancer
Current Proteomics Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition
Current Cancer Drug Targets Recent Trends of Chalcones Potentialities as Antiproliferative and Antiresistance Agents
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction Inhibitors as Radiosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
Clinical Cancer Drugs Epigenetic Regulation of Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Synthetic Lethality and PARP-Inhibitors in Oral and Head & Neck Cancer
Current Pharmaceutical Design